InspireMD’s (NSPR) “Overweight” Rating Reiterated at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of InspireMD (NYSE:NSPR) in a report released on Tuesday, Benzinga reports. Piper Sandler currently has a $4.50 price target on the stock.

Separately, StockNews.com assumed coverage on InspireMD in a research note on Sunday, September 15th. They issued a sell rating for the company.

InspireMD Price Performance

Shares of NSPR stock opened at $2.78 on Tuesday. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.85. The stock’s 50-day moving average is $2.77 and its 200 day moving average is $2.51. The company has a market cap of $69.31 million, a P/E ratio of -3.66 and a beta of 0.90.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The company had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. During the same period in the previous year, the business earned ($0.24) EPS. On average, analysts anticipate that InspireMD will post -0.82 EPS for the current year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. acquired a new position in InspireMD, Inc. (NYSE:NSPR) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned about 0.13% of InspireMD as of its most recent SEC filing. 44.78% of the stock is owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.